274 related articles for article (PubMed ID: 35871241)
1. Tinzaparin-a review of its molecular profile, pharmacology, special properties, and clinical uses.
Amerali M; Politou M
Eur J Clin Pharmacol; 2022 Oct; 78(10):1555-1565. PubMed ID: 35871241
[TBL] [Abstract][Full Text] [Related]
2. The low molecular weight heparin, tinzaparin, in thrombosis and beyond.
Mousa SA
Cardiovasc Drug Rev; 2002; 20(3):199-216. PubMed ID: 12397367
[TBL] [Abstract][Full Text] [Related]
3. Treatment of venous thromboembolism with tinzaparin in oncological patients.
Ageno W; Barni S; Di Nisio M; Falanga A; Imberti D; Labianca RF; Mantovani L
Minerva Med; 2019 Jun; 110(3):251-258. PubMed ID: 30990000
[TBL] [Abstract][Full Text] [Related]
4. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
Holzheimer RG
Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of once daily low molecular weight heparin (tinzaparin sodium) in high risk pregnancy.
Ní Ainle F; Wong A; Appleby N; Byrne B; Regan C; Hassan T; Milner M; Sullivan AO; White B; O'Donnell J
Blood Coagul Fibrinolysis; 2008 Oct; 19(7):689-92. PubMed ID: 18832911
[TBL] [Abstract][Full Text] [Related]
6. Tinzaparin sodium: a review of its pharmacology and clinical use in the prophylaxis and treatment of thromboembolic disease.
Cheer SM; Dunn CJ; Foster R
Drugs; 2004; 64(13):1479-502. PubMed ID: 15212562
[TBL] [Abstract][Full Text] [Related]
7. Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.
Lee AYY; Kamphuisen PW; Meyer G; Bauersachs R; Janas MS; Jarner MF; Khorana AA;
JAMA; 2015 Aug; 314(7):677-686. PubMed ID: 26284719
[TBL] [Abstract][Full Text] [Related]
8. Community-based treatment of venous thromboembolism with a low-molecular-weight heparin and warfarin.
Hyers TM; Spyropoulos AC;
J Thromb Thrombolysis; 2007 Dec; 24(3):225-32. PubMed ID: 17334932
[TBL] [Abstract][Full Text] [Related]
9. Low molecular weight heparins for venous thromboembolism.
Drug Ther Bull; 1998 Apr; 36(4):25-9. PubMed ID: 9684414
[TBL] [Abstract][Full Text] [Related]
10. Safety profile of tinzaparin versus subcutaneous unfractionated heparin in elderly patients with impaired renal function treated for acute deep vein thrombosis: the Innohep® in Renal Insufficiency Study (IRIS).
Leizorovicz A; Siguret V; Mottier D; ; Leizorovicz A; Siguret V; Mottier D; Clonier F; Janas M; Stinson J; Townshend G; Maddalena M
Thromb Res; 2011 Jul; 128(1):27-34. PubMed ID: 21477846
[TBL] [Abstract][Full Text] [Related]
11. Tinzaparin in the treatment of venous thromboembolism.
Pineo GF; Hull RD
Expert Opin Pharmacother; 2003 Dec; 4(12):2355-62. PubMed ID: 14640933
[TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness of low-molecular-weight heparins versus other anticoagulants in major orthopedic surgery: a systematic review and meta-analysis.
Sobieraj DM; Coleman CI; Tongbram V; Chen W; Colby J; Lee S; Kluger J; Makanji S; Ashaye A; White CM
Pharmacotherapy; 2012 Sep; 32(9):799-808. PubMed ID: 22744711
[TBL] [Abstract][Full Text] [Related]
13. Tinzaparin sodium: a low-molecular-weight heparin.
Neely JL; Carlson SS; Lenhart SE
Am J Health Syst Pharm; 2002 Aug; 59(15):1426-36. PubMed ID: 12166042
[TBL] [Abstract][Full Text] [Related]
14. Safety profile of different low-molecular weight heparins used at therapeutic dose.
Gouin-Thibault I; Pautas E; Siguret V
Drug Saf; 2005; 28(4):333-49. PubMed ID: 15783242
[TBL] [Abstract][Full Text] [Related]
15. Selecting an anticoagulant for recurrent venous thromboembolism in cancer.
Goodin S
Am J Health Syst Pharm; 2005 Nov; 62(22 Suppl 5):S10-3. PubMed ID: 16286363
[TBL] [Abstract][Full Text] [Related]
16. Intensive-Dose Tinzaparin in Hospitalized COVID-19 Patients: The INTERACT Study.
Akinosoglou K; Savopoulos C; Pouliakis A; Triantafyllidis C; Markatis E; Golemi F; Liontos A; Vadala C; Papanikolaou IC; Dimakopoulou V; Xarras P; Varela K; Kaiafa G; Mitsianis A; Chatzistamati A; Randou E; Savvanis S; Pavlaki M; Efraimidis G; Samaras V; Papazoglou D; Konstantinidou A; Panagopoulos P; Milionis H; On Behalf Of The Interact Study Group
Viruses; 2022 Apr; 14(4):. PubMed ID: 35458497
[TBL] [Abstract][Full Text] [Related]
17. Tinzaparin sodium: a review of its use in the prevention and treatment of deep vein thrombosis and pulmonary embolism, and in the prevention of clotting in the extracorporeal circuit during haemodialysis.
Hoy SM; Scott LJ; Plosker GL
Drugs; 2010 Jul; 70(10):1319-47. PubMed ID: 20568836
[TBL] [Abstract][Full Text] [Related]
18. CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients.
Lee AY; Bauersachs R; Janas MS; Jarner MF; Kamphuisen PW; Meyer G; Khorana AA;
BMC Cancer; 2013 Jun; 13():284. PubMed ID: 23764005
[TBL] [Abstract][Full Text] [Related]
19. A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism.
Wells PS; Anderson DR; Rodger MA; Forgie MA; Florack P; Touchie D; Morrow B; Gray L; O'Rourke K; Wells G; Kovacs J; Kovacs MJ
Arch Intern Med; 2005 Apr; 165(7):733-8. PubMed ID: 15824291
[TBL] [Abstract][Full Text] [Related]
20. Tinzaparin Safety in Patients With Cancer and Renal Impairment: A Systematic Review.
Vathiotis IA; Syrigos NK; Dimakakos EP
Clin Appl Thromb Hemost; 2021; 27():1076029620979592. PubMed ID: 33464938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
